139 related articles for article (PubMed ID: 4057575)
21. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
22. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.
Lundgren S; Søreide JA; Lea OA
Anticancer Res; 1994; 14(3B):1313-6. PubMed ID: 8067700
[TBL] [Abstract][Full Text] [Related]
23. [Effect of tamoxifen on the content of cytoplasmic steroid hormone receptors of the tumor in patients with cancer of the corpus uteri].
Tsyrlina EV; Sofroniĭ DF; Dil'man VM; Bokhman IaV; Vishnevskiĭ AS
Vopr Onkol; 1989; 35(6):675-80. PubMed ID: 2750079
[TBL] [Abstract][Full Text] [Related]
24. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
[TBL] [Abstract][Full Text] [Related]
25. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
[TBL] [Abstract][Full Text] [Related]
26. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
27. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer.
Namer M; Lalanne C; Baulieu EE
Cancer Res; 1980 May; 40(5):1750-2. PubMed ID: 7371003
[TBL] [Abstract][Full Text] [Related]
28. [Expression of estrogen and progesterone receptors and oncoprotein HER-2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)].
Samsonova EA; Maksimova NA; Urmancheeva AF; Pozharisskiĭ KM
Vopr Onkol; 2004; 50(2):196-201. PubMed ID: 15176223
[TBL] [Abstract][Full Text] [Related]
29. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
Pink D; Lindner T; Mrozek A; Kretzschmar A; Thuss-Patience PC; Dörken B; Reichardt P
Gynecol Oncol; 2006 Jun; 101(3):464-9. PubMed ID: 16368128
[TBL] [Abstract][Full Text] [Related]
30. Hormone steroid receptor variation after tamoxifen administration in endometrial adenocarcinoma from postmenopausal patients.
Di Fronzo G; Ronchi E; Cappelletti V; Luciani L; Coradini D; Oriana S; Miodini P; Andreola S
Cancer Detect Prev; 1986; 9(3-4):323-30. PubMed ID: 3742507
[TBL] [Abstract][Full Text] [Related]
31. [Effect of neoadjuvant therapy with neovir on the level of steroid hormone receptors in endometrial cancer tissue].
Tsyrlina EV; Bakhidze EV; Volkova AT; Kriukova OG; Chepik OF; Maksimov SIa; Bershteĭn LM
Vopr Onkol; 2001; 47(2):214-7. PubMed ID: 11383460
[TBL] [Abstract][Full Text] [Related]
32. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study.
Singh M; Zaino RJ; Filiaci VJ; Leslie KK
Gynecol Oncol; 2007 Aug; 106(2):325-33. PubMed ID: 17532033
[TBL] [Abstract][Full Text] [Related]
33. Correlation between estradiol-17 beta and progesterone cytosol receptor concentration, histologic differentiation and 3H-thymidine incorporation in endometrial carcinoma.
Lindahl B; Alm P; Borg A; Fernö M; Grundsell H; Johnsson JE; Norgren A; Tropé C
Anticancer Res; 1982; 2(4):203-7. PubMed ID: 7149649
[TBL] [Abstract][Full Text] [Related]
34. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action.
Kumar NS; Richer J; Owen G; Litman E; Horwitz KB; Leslie KK
Cancer Res; 1998 May; 58(9):1860-5. PubMed ID: 9581825
[TBL] [Abstract][Full Text] [Related]
35. Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model.
Zaino RJ; Satyaswaroop PG; Mortel R
Cancer Res; 1985 Feb; 45(2):539-41. PubMed ID: 3967228
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen-induced fluorescence as a marker of human breast tumor cell responsiveness to hormonal manipulations: correlation with progesterone receptor content and ultrastructural alterations.
Mouriquand J; Jacrot M; Louis J; Mermet MA; Saez S; Sage JC; Mouriquand C
Cancer Res; 1983 Aug; 43(8):3948-54. PubMed ID: 6861157
[TBL] [Abstract][Full Text] [Related]
37. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
38. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
39. Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy?
Benraad TJ; Friberg LG; Koenders AJ; Kullander S
Acta Obstet Gynecol Scand; 1980; 59(2):155-9. PubMed ID: 7405552
[TBL] [Abstract][Full Text] [Related]
40. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
Hilsenbeck SG; Osborne CK
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1049s-1055s. PubMed ID: 16467123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
